You are here

Firdapse Approved for Treatment of Lambert-Eaton Myasthenic Syndrome

First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection

Firdapse (amifampridine, Catalyst Pharmaceuticals) tablets have been approved by the FDA for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. The rare autoimmune disorder affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients.

Around three in one million individuals worldwide are believed to have LEMS. Patients suffer from significant weakness and fatigue that often causes great difficulties with daily activities. LEMS may be associated with other autoimmune diseases, but typically occurs in patients with cancer such as small cell lung cancer.

In two clinical trials, patients receiving amifampridine experienced a greater benefit than those taking placebo. The most common side effects reported were paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. In addition, seizures have been observed in patients with no history of seizures.

The FDA granted amifampridine priority review, breakthrough therapy, and orphan drug designations.

Source: FDA, November 28, 2018

Recent Headlines

Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over Half of Patients Had Reduced Pain Levels of 30% or More
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications